Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 1.00 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997520 | 0.92 | PIK3CG (0.85) | PIK3CGPABPC1PDPK1SRCMAPT | |
| SCHEMBL11251348 | 0.78 | PIK3CG (0.64) | PIK3CGMAPTKDM4EMEN1USP2 | |
| SCHEMBL11723768 | 0.76 | PIK3CG (0.61) | PIK3CGMAPTKDM4EMEN1USP2 | |
| SCHEMBL10957202 | 0.75 | PIK3CG (0.60) | PIK3CGPABPC1PDPK1SRCMAPT | |
| SCHEMBL3532558 | 0.75 | SRC (0.67) | PIK3CGPABPC1PDPK1SRCKDM4E | |
| SCHEMBL8404114 | 0.75 | PIK3CG (0.60) | PIK3CGMAPTKDM4EMEN1USP2 | |
| SCHEMBL10956299 | 0.75 | PABPC1 (1.00) | PIK3CGPABPC1PDPK1SRCMAPT | |
| SCHEMBL11602923 | 0.75 | PIK3CG (0.60) | PIK3CGPABPC1MAPTKDM4EMEN1 | |
| SCHEMBL11351464 | 0.75 | PIK3CG (0.59) | PIK3CGSRCMAPTKDM4EMEN1 | |
| SCHEMBL5157381 | 0.74 | PIK3CG (0.58) | PIK3CGMAPTKDM4EMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11209421-B2 | Cytidine deaminase expression level in cancer as a new therapeutic target | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-28 | — | — | US | disclosed |
| US-20190293629-A1 | CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-26 | — | — | US | disclosed |
| EP-3436601-A1 | CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET | Centre National De La Recherche Scientifique (FR) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017167989-A1 | CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-10-05 | — | — | WO | disclosed |
| US-20050153961-A1 | 1, 2, 4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents | LEE WILLIAM W (US) | 2005-07-14 | — | — | US | disclosed |
| US-6828321-B2 | Compounds specifically radiosensitize hypoxic tumor cells | SRI INTERNATIONAL | 2004-12-07 | — | — | US | disclosed |
| US-6362184-B1 | KILLING TUMOR CELLS | SRI INTERNATIONAL | 2002-03-26 | — | — | US | disclosed |
| EP-0478545-A4 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | STANFORD RES INST INT (US) | 1992-08-05 | — | — | EP | disclosed |
| EP-0478545-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1992-04-08 | — | — | EP | disclosed |
| WO-1991004028-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-04-04 | — | — | WO | disclosed |
| EP-0413706-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-02-27 | — | — | EP | disclosed |
| WO-1989008647-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1989-09-21 | — | — | WO | disclosed |
| US-4550168-A | Benzisoselenazolones and a process for the treatment of inflammatory diseases | A. NATTERMANN & CIE GMBH (DE) | 1985-10-29 | — | — | US | disclosed |
| EP-0100899-A2 | Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them | A. Nattermann & Cie. GmbH (DE) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153961-A1 | 1, 2, 4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents | HYOU1, HIF1AN, HIF1A | PIK3CG 4002/4885PABPC1 1254/4885PDPK1 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.